I'm now predicting BUBS will trade below $0.20 following the next quarterly, due no later than April 28th 2023.
The only news due in 2023 which will bounce the price is SAMR approval. USFDA not due until early 2025.
The short positions keep slowly accumulating.
If SAMR is rejected, the CEO will finally capitulate.
I think the SAMR outcome is a critical juncture for BUBS in 2023.
Given the China trade relationship and recent AUKUS developments, I think the Australian ties to BUBS SAMR Application will render it a low likelihood for approval.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.005(3.23%) |
Mkt cap ! $142.9M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 15.5¢ | $145.4K | 921.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 954274 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 1285294 | 25 |
View Market Depth
| Last trade - 16.11pm 24/06/2025 (20 minute delay) ? |
| BUB (ASX) Chart |